ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

ADCT ADC Therapeutics SA

4.46
0.02 (0.45%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ADC Therapeutics SA ADCT NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.02 0.45% 4.46 18:51:24
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.44 4.21 4.51 4.34 4.44
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/4/202406:00GLOBEADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial..
03/4/202406:00GLOBEADC Therapeutics to Host a Virtual Research Investor Event..
01/4/202415:05GLOBEADC Therapeutics Makes Grants to New Employees Under..
13/3/202406:03IHMARKETNEWSMixed Futures Amidst Quiet Economic Schedule; Oil Prices..
13/3/202406:00GLOBEADC Therapeutics Reports Fourth Quarter and Full Year 2023..
06/3/202406:15GLOBEADC Therapeutics to Participate in the Guggenheim 5th Annual..
06/3/202406:00GLOBEADC Therapeutics to Host Fourth Quarter and Year-End 2023..
05/3/202416:45GLOBEADC Therapeutics Announces Abstracts Accepted for..
05/3/202408:15EDGAR2Form 8-K - Current report
29/2/202415:30EDGAR2Form 8-K - Current report
27/2/202406:00GLOBEADC Therapeutics to Participate in the TD Cowen 44th Annual..
24/1/202407:00EDGAR2Form 8-K - Current report
19/1/202415:30EDGAR2Form 8-K - Current report
04/1/202406:15EDGAR2Form 8-K - Current report
04/1/202406:15GLOBEADC Therapeutics Regains Compliance with NYSE Continued..
04/1/202406:00EDGAR2Form 8-K - Current report
04/1/202406:00GLOBEADC Therapeutics Provides Business Updates
02/1/202419:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202419:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202419:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202419:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202418:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202418:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/12/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202315:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/12/202304:15GLOBEADC Therapeutics Announces Initial Results from..
04/12/202315:57EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/11/202301:40PRNUSSobi to present new data at ASH 2023 Annual Meeting
15/11/202302:00GLOBEMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur..
07/11/202306:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202306:15GLOBEADC Therapeutics Receives NYSE Notice of Non-Compliance With..
07/11/202306:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202306:00GLOBEADC Therapeutics Reports Third Quarter 2023 Financial..
06/11/202306:00GLOBEADC Therapeutics to Participate in the Jefferies London..
02/11/202309:10GLOBEADC Therapeutics Announces Abstracts Accepted for..
24/10/202306:00GLOBEADC Therapeutics to Host Third Quarter 2023 Financial..
04/10/202303:00GLOBEMyricx Expands its ADC Expertise with the Appointment of..
11/9/202306:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202306:00GLOBEADC Therapeutics to Participate in September Investor..
30/8/202318:32GLOBEADC Therapeutics Announces Updates on ZYNLONTA® LOTIS..
08/8/202306:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/8/202306:00GLOBEADC Therapeutics Reports Second Quarter 2023 Financial..
01/8/202306:00GLOBEADC Therapeutics to Host Second Quarter 2023 Financial..
24/7/202306:21GLOBEOverland ADCT BioPharma Announces NMPA Accepts Biologics..
20/7/202315:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/7/202315:05GLOBEADC Therapeutics Announces Plan to Discontinue the Phase 2..
11/7/202308:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202306:00GLOBEADC Therapeutics Announces Voluntary Pause of Enrollment in..
15/6/202306:15GLOBEADC Therapeutics Announces Evolution of Board of Directors
09/6/202306:15GLOBEADC Therapeutics Announces Updated LOTIS-2 Results..

Su Consulta Reciente

Delayed Upgrade Clock